Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Oxford Health Plan (OXHP) -- Ignore unavailable to you. Want to Upgrade?

To: Thomas Haegin who wrote (580)	12/16/1997 6:05:00 AM
From: robt justine	Read Replies (1) \| Respond to of 2068

Hi Thomas: Thank you for your balanced and open-minded response to my post. My point of the advances was not that they should be reclaimed. Obviously, for cash flow purposes, these payments will be netted against the total amount due each hospital, doctor, and doctor's group. The company informed many of these payees that the payments should be considered a loan until full settlement of each account. It is my strong belief that a part of the $271M was treated as such. Now, if I am a regulator coming into their offices playing hardball, then since these accounts have technically not been paid down they must be fully reserved for. When the accounts are correctly settled against these "loans" then the reserve can be backed out. I believe that one should follow the cash and be aware of its accounting in the regulators eyes. I somehow failed in my attempts to get this point across to Michael Burry.